All In Biotech

Drug Trial Radar · NCT07093970

A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors

A Phase I/II, Open-label, Multi-center, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of MRG006A in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

343

Planned (sponsor's estimate)

Start

Jul 24, 2024

Primary completion

Dec 2027

Study completion Dec 2028

Sponsor

Lead sponsor
Lepu Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Jul 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 17 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG006A in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • MRG006ADrug

    Administrated intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD) - Phase ITime frame: Baseline to the end of the first treatment cycle (each cycle is 21 days).
  2. Recommended Phase II Dose (RP2D) - Phase ITime frame: Baseline to study completion (up to 24 months).
  3. Adverse Events (AEs) - Phase ITime frame: Baseline to 30 days after the last dose of study treatment.
  4. Serious Adverse Events (SAEs) - Phase ITime frame: Baseline to 30 days after the last dose of study treatment.
  5. Objective Response Rate (ORR)- Phase IITime frame: Baseline to study completion (up to 24 months).

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

  • Zhongshan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.